Antisense oligonucleotide targeting transthyretin (TTR)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Antisense oligonucleotide targeting transthyretin (TTR), covering 2016-08-10 to 2016-08-10. Get the full timeline:
Most recent: Clinical Trial Update: The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart [Phase 2]